Sanofi India Ltd

Sanofi India Ltd maintains a strong liquidity position, with a current ratio of 1.63 and cash and equivalents amounting to INR 2.3 billion. The company's liquidity risk is assessed as low, supported by its operating cash flow of INR 4.38 billion and minimal long-term debt of INR 178 million. However, the company reported negative free cash flow of INR -1.04 billion, primarily due to capital expenditures of INR -257 million. The company's profitability is robust, with a return on equity (ROE) of 43.61% and a return on assets (ROA) of 26.04%. These figures significantly exceed the typical benchmarks for the pharmaceutical industry, indicating efficient use of equity and assets. The gross profit margin stands at 50.0%, while the operating margin is 23.3%, both of which are in line with industry norms. Sanofi India Ltd's revenue is concentrated in a single geographic segment, India, which accounts for 100% of its total revenue. The company does not disclose revenue by product segments, but its primary business is in prescription medicines and vaccines. This geographic concentration exposes the company to regulatory and macroeconomic risks specific to the Indian market. The company's growth trajectory is stable, with no significant revenue growth or decline reported in the latest financial period. The company's outlook for the current fiscal year is neutral, with no projected changes in revenue or operating income. Analysts have provided a mean price target of INR 4,656, with a median of INR 4,487, suggesting a generally positive sentiment. The risk assessment for Sanofi India Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio is 0.02, indicating a conservative capital structure. The company has not issued new shares recently, and there are no indications of near-term dilution pressure. Recent events and disclosures for Sanofi India Ltd include standard financial reporting and analyst estimates. There are no material events or regulatory actions reported in the latest filings that would significantly impact the company's operations or financial position.